Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Paroxetine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | GRK2 | P25098 | 4/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | NPC1 | O15118 | 1/20 | 1.00 |
| ▸ | CACNA1F | O60840 | 1/20 | 1.00 |
| ▸ | MPO | P05164 | 1/20 | 1.00 |
| ▸ | ADRB2 | P07550 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | CHRM4 | P08173 | 1/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | CHRM5 | P08912 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Paroxetine SCHEMBL29358021 | 1.00 | CYP3A4 (1.00) | CYP3A4GRK2SLC6A4TP53CYP1A2 | |
| Paroxetine SCHEMBL2583823 | 1.00 | CYP3A4 (1.00) | CYP3A4GRK2SLC6A4TP53CYP1A2 | |
| Paroxetine SCHEMBL10643985 | 1.00 | CYP3A4 (1.00) | CYP3A4GRK2SLC6A4TP53CYP1A2 | |
| Paroxetine SCHEMBL1286957 | 1.00 | CYP3A4 (1.00) | CYP3A4GRK2SLC6A4TP53CYP1A2 | |
| Paroxetine SCHEMBL8732632 | 1.00 | CYP3A4 (1.00) | CYP3A4GRK2SLC6A4TP53CYP1A2 | |
| Paroxetine SCHEMBL15855060 | 1.00 | CYP3A4 (1.00) | CYP3A4GRK2SLC6A4TP53CYP1A2 | |
| Paroxetine SCHEMBL1560678 | 1.00 | CYP3A4 (1.00) | CYP3A4GRK2SLC6A4TP53CYP1A2 | |
| Paroxetine SCHEMBL27799 | 1.00 | CYP3A4 (1.00) | CYP3A4GRK2SLC6A4TP53CYP1A2 | |
| Paroxetine SCHEMBL1945816 | 1.00 | CYP3A4 (1.00) | CYP3A4GRK2SLC6A4TP53CYP1A2 | |
| Paroxetine SCHEMBL10643980 | 1.00 | CYP3A4 (1.00) | CYP3A4GRK2SLC6A4TP53CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 340 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060264637-A1 | PREPARATION OF PAROXETINE HYDROCHLORIDE HEMIHYDRATE | DR. REDDY'S LABORATORIES LIMITED (IN) | 2006-11-23 | — | — | US | claimed |
| WO-1996001106-A1 | USE OF PHARMACEUTICAL AGENTS FOR ALLEVIATION OR TREATMENT OF THE IMMUNE DYSFUNCTION RELATED TO INFECTION WITH HUMAN IMMUNODEFICIENCY VIRUSES (HIV) OR RELATED VIRUSES | HOFMANN BO ARNE (DK) | 1996-01-18 | — | — | WO | claimed |
| WO-1996001107-A1 | USE OF PHARMACEUTICAL AGENTS FOR RESTORING, ALLEVIATION, OR TREATMENT OF IMMUNODEFICIENCY, INCLUDING THE ALLEVIATION OR TREATMENT OF THE IMMUNE DYSFUNCTION RELATED TO INFECTION WITH HUMAN IMMUNODEFICIENCY VIRUSES (HIV) OR RELATED VIRUSES | HOFMANN BO ARNE (DK) | 1996-01-18 | — | — | WO | claimed |
| EP-4687890-A1 | METHODS FOR TREATING DEPRESSIVE STATES | BioXcel Therapeutics, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| WO-2024211911-A1 | METHODS FOR TREATING DEPRESSIVE STATES | OAKTREE FUND ADMINISTRATION, LLC (US) | 2024-10-10 | — | — | WO | disclosed |
| CN-117750956-A | Methods for treating depressive states | 比奥克斯塞尔医疗股份有限公司 | 2024-03-22 | — | — | CN | disclosed |
| WO-2022257981-A1 | USE OF COMPOUNDS IN INHIBITING OR KILLING MITES AND TREATING DRY-EYE SYNDROME | 广州岐微生物医药科技有限公司 | 2022-12-15 | — | — | WO | disclosed |
| US-20200289501-A1 | CARBOSTYRIL DERIVATIVES AND SEROTONIN REUPTAKE INHIBITORS FOR TREATMENT OF MOOD DISORDERS | OTSUKA PHARMA CO LTD (JP) | 2020-09-17 | — | — | US | disclosed |
| US-20190151308-A1 | CARBOSTYRIL DERIVATIVES AND SEROTONIN REUPTAKE INHIBITORS FOR TREATMENT OF MOOD DISORDERS | OTSUKA PHARMA CO LTD (JP) | 2019-05-23 | — | — | US | disclosed |
| US-9938525-B2 | Compositions and methods for selective delivery of oligonucleotide molecules to cell types | NLIFE THERAPEUTICS, S.L. (ES) | 2018-04-10 | — | — | US | disclosed |
| EP-1434763-B1 | BETA-LACTAMYL VASOPRESSIN V1A ANTAGONISTS | AZEVAN PHARMACEUTICALS INC (US) | 2018-01-17 | — | — | EP | disclosed |
| US-5614523-A | INDOLYLOXY COMPOUNDS | ELI LILLY AND COMPANY (US) | 1997-03-25 | — | — | US | disclosed |
| EP-0759299-A1 | Potentiation of serotonin response | ELI LILLY AND COMPANY (US) | 1997-02-26 | — | — | EP | disclosed |
| EP-0747049-A1 | Use of tachykinin antagonists in combination with serotonin agonists or serotonin reuptake inhibitors for the manufacture of a medicament for the treatment of allergic rhinitis | ELI LILLY AND COMPANY (US) | 1996-12-11 | — | — | EP | disclosed |
| US-5576321-A | ALKOXY-SUBSTITUTED INDOLES | ELI LILLY AND COMPANY (US) | 1996-11-19 | — | — | US | disclosed |
| WO-1996022290-A1 | COMPOUNDS HAVING EFFECTS ON SEROTONIN-RELATED SYSTEMS | ELI LILLY AND COMPANY (US) | 1996-07-25 | — | — | WO | disclosed |
| EP-0722941-A2 | Compounds having effects on serotonin-related systems | ELI LILLY AND COMPANY (US) | 1996-07-24 | — | — | EP | disclosed |
| EP-0714663-A2 | Potentiation of drug response by a serotonin 1A receptor antagonist | ELI LILLY AND COMPANY (US) | 1996-06-05 | — | — | EP | disclosed |
| WO-1996001106-A1 | USE OF PHARMACEUTICAL AGENTS FOR ALLEVIATION OR TREATMENT OF THE IMMUNE DYSFUNCTION RELATED TO INFECTION WITH HUMAN IMMUNODEFICIENCY VIRUSES (HIV) OR RELATED VIRUSES | HOFMANN BO ARNE (DK) | 1996-01-18 | — | — | WO | disclosed |
| EP-0266574-B1 | Piperidine compounds and their preparation and use | NOVO NORDISK AS (DK) | 1994-01-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200289501-A1 | CARBOSTYRIL DERIVATIVES AND SEROTONIN REUPTAKE INHIBITORS FOR TREATMENT OF MOOD DISORDERS | HTR5A, SLC6A4, HTR4 | SLC6A4 2/4885CYP3A4 96/4885GRK2 278/4885 |
| US-20190151308-A1 | CARBOSTYRIL DERIVATIVES AND SEROTONIN REUPTAKE INHIBITORS FOR TREATMENT OF MOOD DISORDERS | HTR5A, SLC6A4, HTR4 | SLC6A4 2/4885CYP3A4 96/4885GRK2 278/4885 |
| US-20060264637-A1 | PREPARATION OF PAROXETINE HYDROCHLORIDE HEMIHYDRATE | HTR5A, HTR6, HTR2B | SLC6A4 22/4885CYP3A4 36/4885GRK2 2254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.